Get started
HUMANA INC DRNHUMANA INC DRNHUMANA INC DRN

HUMANA INC DRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

H1UM34 trade ideas

HUM Long 11/10/24Asset Class: Stocks Income Type: Weekly Symbol: HUM Trade Type: Long Trends: Short Term: Up Long Term: Down Set-Up Parameters: Entry: 251.55 Stop: 227.76 TP1 321.05 (3:1) Trade idea: Daily DZ DBR at breakout, with a FVG above it at 1:1 RRR. Possible trend reversal at the daily DZ !!Be aware of pending Economic Reports. If price is within 20 pips of proximal value at time of major impact report, then Confirmation entry. Trade management: **When price hits 1:1 or T1, consider moving stop to entry in case of pullback. **Disclaimer**: The trading strategies, ideas, and information shared are for educational and informational purposes only. They do not constitute financial advice or a recommendation to buy or sell any securities, currencies, or financial instruments. You should do your own research or consult with a licensed financial advisor before making any trading decisions. The author assumes no responsibility for any losses incurred from following these trading ideas.
NYSE:HUMLong
by MESHANL
1
Hum value swingI like to categorize my swing trades into sections. For longer term trades I like to buy 6 month or LEAP calls. In this case I believe Hum has fallen below intrinsic value fairly decently. I look to fill the gap at 278$ for my first target. The company is doing fine, revenues continue to grow, margins remain low but this is health insurance. I expect a full recovery of the entire massive candle around 350$ within the next 6-8 months. My plan: 260$ Calls 6 months out 300$ Calls 18 months out PT1= dashed green the GAP on the daily PT2= 358$ hitting that second fib
NYSE:HUMLong
by Apollo_21mil
Humana | HUM | Long at $220.00Humana NYSE:HUM took a nosedive to "crash" levels (based on my selected simple moving averages (SMA)) this morning after a lower-performance rating for a widely used Medicare insurance plan is expected to hurt enrollments for 2025 (and will potentially hit the health insurer's revenue and bonus payments in 2026). However, I view this massive drop as an opportunity for an initial long entry for a great value stock. The company is strong, highly rated among patients, and solid fundamentals despite the anticipated earnings drop. From a technical analysis perspective, it touched my "crash" SMA, but may dip further after a dead cat bounce to the $190s in the coming days or weeks. But, predicting true bottom is a fool's game, so at $220.00, NYSE:HUM is in a personal buy zone for an initial long entry. Target #1 = $250.00 Target #2 = $275.00 Target #3 = $314.00 Target #4 = $340.00
NYSE:HUMLong
by NicksAnalysis
HUM eyes on $275 for major support: time to start buying?Humana has been dumping for a while now. Just dropped hard into a major support zone. Scary entry here, but tight stop loss is possible. There are many layers of resistance above. So there will be many battles on the way up. Maybe scalp or sell+buy pieces to build position. I know nothing about this company or insurance. But it pays good dividends and it is an insurance! Long-term dollar-averaging entry could start here. $ 274.86 - 280.07 is the major support for entry $ 326.52 - 327.87 is the first major resistance. $ 250.50 - 251.76 is next major support below. =========================================== .
NYSE:HUM
by EuroMotif
Bottom in for Humana? If so, that's a nice dip! Humana Inc. (HUM) recently experienced a significant drop of about 40%, landing on a 10-year support line. Is this the end of the decline for Humana? If so, this could present a very good buying opportunity. - The RCI 3 line indicator shows a triple bottom. - The RSI was oversold, reaching around 18, and has crossed above the moving average. - The chart displays a rare buying signal, last seen in May 2019. If the price recovers, a profit of 50% is possible. What do you think?
NYSE:HUMLong
by ValerianK
HUM Slide 14.67% Amidst Increase in Medicare Advantage PlansHumana's ( NYSE:HUM ) stock has experienced a significant decline of almost 15% in early trading on Tuesday, following the Centers for Medicare & Medicaid Services (CMS) announcement of a 3.7% increase in federal payments to Medicare Advantage plans. This increase matches the percentage increase proposed in January, leading to disappointment among investors and concerns regarding health insurers' profit margins, given the rising costs of medical care. The CMS has projected that the federal government will contribute between $500 billion and $600 billion in Medicare Advantage payments to private health plans in 2025, to maintain the stability of the program and ensure that payments are up-to-date and accurate. Humana's CFO, Susan Diamond, had previously informed investors that the health insurer would fall short of its upper earnings-per-share growth target without a more significant increase in payments. The payment revision, which excludes the estimated growth in patient risk scores, represents a 0.16% decline, leading to disappointment among investors and health insurers who had lobbied for a higher increase. Research from JPMorgan cited by Bloomberg revealed that there has only been one instance in the past decade where Medical Advantage plan final rates have not increased from the government's initial rate proposals. Other health insurers, including CVS Health, UnitedHealth Group, and Centene, have also experienced declines following the news, losing 5.9%, 4.5%, and 2.3%, respectively, in after-hours trading. However, Humana has been hit the hardest, with the stock falling 14.65% to $299.70 in early morning trading on Tuesday, putting it at levels not seen since the early days of the pandemic in March 2020. Technical Outlook With the Relative Strength Index (RSI) at 20 a break below the ceiling of the falling wedge is imminent thereby forming a new support at that level and spike after any major fundamentals. Allowing buyers to stack at that level. Investors should keep an eye on a key horizontal trendline that stretches back to the stock's April 2020 pandemic recovery, an area that may attract buying interest around $318, amid Tuesday's expected news-driven sell-off to a multi-year low.
NYSE:HUMShort
by DEXWireNews